Abstract:Multifunctional platinumIV anticancer prodrugs have the potential to enrich the anticancer properties and overcome the clinical problems of drug resistance and side effects of platinumII anticancer agents. Herein, we develop dual and triple action platinumIV complexes with targeted and biological active functionalities. One complex (PFL) that consists of cisplatin, tegafur, and lonidamine exhibits strong cytotoxicity against triple negative breast cancer (TNBC) cells. Cellular uptake and distribution studies reveal that PFL mainly accumulates in mitochondria. As a result, PFL disrupts the mitochondrial ultrastructure and induces significant alterations in the mitochondrial membrane potential, which further leads to an increase in production of reactive oxygen species (ROS) and a decrease in ATP synthesis in MDA-MB-231 TNBCs. Western blot analysis reveals the formation of ternary complex of thymidylate synthase, which shows the intracellular conversion of tegafur into 5-FU after its release from PFL. Furthermore, treatment with PFL impairs the mitochondrial function, leading to the inhibition of glycolysis and mitochondrial respiration and induction of apoptosis through the mitochondrial pathway. The RNA-sequencing experiment shows that PFL can perturb the pathways involved in DNA synthesis, DNA damage, metabolism, and transcriptional activity. These findings demonstrate that PFL intervenes in several cellular processes including DNA damage, thymidylate synthase inhibition, and perturbation of the mitochondrial bioenergetics to kill the cancer cells. The results highlight the significance of a triple-action prodrug for efficient anticancer therapy for TNBCs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.inorgchem.0c01736?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.inorgchem.0c01736</a>.Supporting experimental methods; characterization of the complexes; stability data; reduction of the complexes by AA; Hoechst staining; ATP assay and RNA-seq data (<a class="ext-link" href="/doi/suppl/10.1021/acs.inorgchem.0c01736/suppl_file/ic0c01736_si_001.pdf">PDF</a>)List of genes that are up-regulated or down-regulated (<a class="ext-link" href="/doi/suppl/10.1021/acs.inorgchem.0c01736/suppl_file/ic0c01736_si_002.xlsx">XLSX</a>)List of transcription factor (TF) genes that are up-regulated or down-regulated (<a class="ext-link" href="/doi/suppl/10.1021/acs.inorgchem.0c01736/suppl_file/ic0c01736_si_003.xlsx">XLSX</a>)This article has not yet been cited by other publications.

Platinum(IV)-Gold(I) Agents with Promising Anticancer Activity: Selected Studies in 2D and 3D Triple-Negative Breast Cancer Models

In Vitro and In Vivo Relevant Antineoplastic Activity of Platinum(II) Complexes toward Triple-Negative MDA-MB-231 Breast Cancer Cell Line

Synthesis and Biological Activity of Binuclear Platinum Complexes Containing Two Monofunctional Cis-[Pt(Nh3)(2)Cl](+) Units Bridged by 4,4 '-Dipyridyl Selenides or Sulfides

Platinum(0)-η2-1,2-(E)ditosylethene Complexes Bearing Phosphine, Isocyanide and N-Heterocyclic Carbene Ligands: Synthesis and Cytotoxicity towards Ovarian and Breast Cancer Cells

Anticancer Effect of PtIIPHEN SS, PtII5ME SS, PtII56ME SS and Their Platinum(IV)-Dihydroxy Derivatives against Triple-Negative Breast Cancer and Cisplatin-Resistant Colorectal Cancer

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Mesoporous Silica Nanoparticles Enhance the Anticancer Efficacy of Platinum(IV)-Phenolate Conjugates in Breast Cancer Cell Lines

Platinum(II) N -heterocyclic carbene complexes arrest metastatic tumor growth

A monofunctional Pt(II) complex combats triple negative breast cancer by triggering lysosome-dependent cell death

Antiproliferative Activity of Platinum(II) and Copper(II) Complexes Containing Novel Biquinoxaline Ligands

New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status

Engineering Novel Amphiphilic Platinum(IV) Complexes to Co-Deliver Cisplatin and Doxorubicin

A Dual Approach to Cancer Treatment: Gold(I) Terpyridine Derivatives as DNA Binders and Inhibitors of Mammalian Thioredoxin Reductase

Synthesis and biological evaluation of new mono naphthalimide platinum(IV) derivatives as antitumor agents with dual DNA damage mechanism

New nano-complexes targeting protein 3S7S in breast cancer and protein 4OO6 in liver cancer investigated in cell line

Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem

Co-targeting CDK 4/6 and C-MYC/STAT3/CCND1 axis and inhibition of tumorigenesis and epithelial-mesenchymal-transition in triple negative breast cancer by Pt(II) complexes bearing NH3 as trans-co-ligand

In Vitro Anticancer Activity of Nanoformulated Mono- and Di-nuclear Pt Compounds

Synthesis and Antitumor Activity of Dinuclear Platinum Complexes with (1(i)R, 1(ii)R, 2(i)R, 2(ii)R)-N-i,N-ii-(1, 3-Phenylenebis(methylene))dicyclohexane-1, 2-diamie as the Ligand

Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer

Platinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural Factor